General Studies 2022 GS Paper III 15 marks 250 words Compulsory Explain

Q16

What is the basic principle behind vaccine development? How do vaccines work? What approaches were adopted by the Indian vaccine manufacturers to produce COVID-19 vaccines? (Answer in 250 words) 15

हिंदी में प्रश्न पढ़ें

वैक्सीन विकास का आधारभूत सिद्धांत क्या है? वैक्सीन कैसे कार्य करते हैं? कोविड-19 टीकों के निर्माण हेतु भारतीय वैक्सीन निर्माताओं ने क्या-क्या पद्धतियां अपनाई हैं? (250 शब्दों में उत्तर दीजिए)

Evaluate your answer to this question → See all 2022 General Studies questions

Directive word: Explain

This question asks you to explain. The directive word signals the depth of analysis expected, the structure of your answer, and the weight of evidence you must bring.

See our UPSC directive words guide for a full breakdown of how to respond to each command word.

How this answer will be evaluated

Approach

The question demands a clear explanation of vaccine science followed by specific Indian approaches to COVID-19 vaccine development. Structure as: brief intro defining vaccine principle → body covering mechanism of action (immune response) → detailed section on Indian manufacturers' platforms (viral vector, inactivated, DNA) → concluding with significance for Atmanirbhar Bharat and global vaccine equity.

Key points expected

  • Basic principle: exposing immune system to antigen (weakened/inactivated pathogen or component) to generate memory response without causing disease
  • Mechanism: antigen presentation → activation of B-cells (antibody production) and T-cells → formation of immunological memory → rapid response upon actual infection
  • Covaxin (Bharat Biotech): inactivated whole virion platform using Vero cell technology, developed with ICMR-NIV
  • Covishield (SII): viral vector platform (recombinant chimpanzee adenovirus), technology transfer from Oxford-AstraZeneca
  • ZyCoV-D (Zydus Cadila): DNA plasmid platform, needle-free delivery, India's first DNA vaccine
  • Significance: demonstrated indigenous R&D capacity, technology transfer capabilities, and contribution to COVAX and vaccine diplomacy

Evaluation rubric

DimensionWeightMax marksExcellentAveragePoor
Demand-directive understanding20%3Correctly identifies three distinct explanatory tasks—principle, mechanism, and Indian approaches—and addresses each proportionally without conflating them; uses scientific terminology accurately (antigen, immunological memory, platform technologies)Addresses all three parts but conflates principle with mechanism or gives disproportionate space; uses generic terms like 'protection' instead of specific immunological conceptsMisses one or more parts entirely; confuses vaccine types with treatment modalities; fails to distinguish between principle and mechanism
Content depth & accuracy20%3Precisely describes innate and adaptive immune response; accurately distinguishes inactivated, viral vector, and DNA platforms with correct technical details (Vero cells, chimpanzee adenovirus, plasmid DNA); names specific institutions (ICMR-NIV, SII, Bharat Biotech)Basic immune response described but lacks specificity on cellular mechanisms; mentions vaccine types but with technical inaccuracies; identifies manufacturers but misses platform distinctionsFundamental scientific errors (e.g., vaccines treat disease, antibodies attack pathogens directly); confuses Covaxin with Covishield; omits platform technologies entirely
Structure & flow20%3Clear tripartite structure with seamless transitions; principle → mechanism builds logical foundation before Indian case studies; 250-word discipline maintained with balanced weighting (~60 words per section)All parts present but abrupt transitions; uneven weighting (overlong on principle, skimpy on Indian approaches); readable but mechanical structureDisorganized or missing structure; jumps between concepts without logical progression; significantly over/under word limit
Examples / case-law / data20%3Specific naming of Covaxin, Covishield, ZyCoV-D with manufacturers, platform technologies, and institutional partnerships; references to emergency use authorization timelines or export quantities (e.g., Vaccine Maitri)Names 2-3 vaccines correctly but misses manufacturers or platforms; generic reference to 'Indian vaccines' without specificity; no quantitative or timeline dataNo specific Indian examples; only mentions 'Serum Institute' without vaccine name; includes factually wrong pairings (e.g., Covaxin as viral vector)
Conclusion & analytical edge20%3Synthesizes scientific capacity with strategic autonomy (Atmanirbhar Bharat) and global health leadership; critically notes platform diversity as risk mitigation or addresses equity/ IPR dimensions brieflyPositive summary of achievement without synthesis; generic statement on 'proud moment for India'; no critical or forward-looking elementAbsent or abrupt conclusion; merely lists points already made; includes irrelevant digression on pandemic management unrelated to vaccine development

Practice this exact question

Write your answer, then get a detailed evaluation from our AI trained on UPSC's answer-writing standards. Free first evaluation — no signup needed to start.

Evaluate my answer →

More from General Studies 2022 GS Paper III